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Abstract
Introduction: A high BMI during and after pregnancy is linked to poor pregnancy outcomes and contributes to
long-term maternal obesity, hypertension, and diabetes. Evidence of feasible, effective postnatal interventions is
lacking. This randomised controlled trial will assess the feasibility of conducting a future definitive trial to determine
effectiveness and cost-effectiveness of lifestyle information and access to Slimming World® (Alfreton, UK) groups for
12 weeks commencing from 8 to 16 weeks postnatally, in relation to supporting longer-term postnatal weight
management in women in an ethnically diverse inner city population.
Methods/analysis: Women will be recruited from one maternity unit in London. To be eligible, women will be
overweight (BMI 25–29.9 kg/m2) or obese (BMI ≥ 30 kg/m2) as identified at their first antenatal contact, or have a
normal BMI (18.5–24.9 kg/m2) at booking but gain excessive gestational weight as assessed at 36 weeks gestation.
Women will be aged 18 and over, can speak and read English, expecting a single baby, and will not have accessed
weight management groups in this pregnancy. Women will be randomly allocated to standard care plus lifestyle
information and access to Slimming World® (Alfreton, UK) groups or standard care only. A sample of 130 women is
required.
Feasibility trial objectives reflect those considered most important inform a decision about undertaking a definitive
future trial. These include estimation of impact of lifestyle information and postnatal access to Slimming World®
(Alfreton, UK) on maternal weight change between antenatal booking weight and weight at 12 months postbirth,
recruitment rate and time to recruitment, retention rate, influence of lifestyle information and Slimming World®
(Alfreton, UK) groups on weight management, diet, physical activity, breastfeeding, smoking cessation, alcohol
intake, physical and mental health, infant health, and health-related quality of life 6 and 12 months postnatally.
An embedded process evaluation will assess acceptability of study processes and procedures to women.
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Strengths and limitations of this study
 Postnatal interventions may be more effective than
antenatal interventions at supporting weight
management among women with higher BMIs, but
evidence is needed.
 This feasibility trial will assess if women with high
BMIs at pregnancy commencement or have normal
BMIs but gain excessive gestational weight would be
prepared to be randomised to standard care plus
Slimming World® (Alfreton, UK) groups offered from
8 to 16 weeks postnatally, or to standard care only.
 Women will only be recruited from one study site;
however, the site provides maternity care to a
population with wide diversity. The intervention is
available UK-wide.
 Blinding of study participants and assessors is not possible.
Introduction
At around 6 to 8 weeks postnatally, two thirds of women
weigh more than their pre-pregnancy weight [1], with
evidence that women who commence subsequent preg-
nancies overweight or obese have higher risk of adverse
outcomes for themselves and/or for their infants. Fur-
thermore, a high BMI before, during, and after preg-
nancy is linked to poor maternal health behaviours
including smoking, lack of regular exercise, and not
breastfeeding [2–4]. Maintaining a high BMI postnatally
is an important predictor of maternal future weight gain
and obesity, hypertension, diabetes, and degenerative
joint disease [5–7], with infants of obese women at
greater risk of higher BMI and blood pressure in child-
hood and young adulthood [4]. In the absence of evi-
dence to support the benefit of pregnancy weight
management interventions and positive lifestyle behav-
iours, postnatal interventions are viewed as increasingly
important [8, 9] in terms of enhancing life-course health
and preventing adverse outcomes in subsequent preg-
nancies, but knowledge of how best to support and treat
overweight or obese individuals, including postnatal
women, remains a challenge [10, 11]. The timing of
commencement, recruitment approaches, and content of
postnatal interventions are unclear [5], including how
best to ensure that socio-economic influences which
may impact on maternal health and lifestyle behaviours
are considered. This is important, as a significantly greater
proportion of women from areas of high social deprivation
in the UK have weight management problems [12], find-
ings supported with work from the USA where excessive
pregnancy weight gain and failure to lose weight were
found to be highly prevalent among young, low income,
ethnic minority women in one large cohort study [13].
Although around half of all UK women of reproduct-
ive age are overweight or obese [14], UK public health
guidance does not recommend dieting and weight loss
during pregnancy due to concerns about impact on in-
fant outcomes [15] despite lack of evidence [16], and
there is no current UK guidance on recommended preg-
nancy weight gain. Pregnancy-only interventions have
measured impact on adverse outcomes including gesta-
tional diabetes, large for gestational age infants and cae-
sarean births [17–20]. UPBEAT, a UK-based multicentre
trial of a behavioural intervention based on changing
diet to foods with a lower glycaemic index and increas-
ing physical activity, aimed to reduce risk of gestational
diabetes and large for gestational age infants [21]; 1555
women with a mean BMI of 36.3 kg/m2 (SD 4.8) were
recruited. No differences were found in incidence of out-
comes of interest. Gestational diabetes was reported in
172 (26%) women in standard care compared with 160
(25%) in the intervention group (risk ratio 0.96, 95% CI
0.79–1.16; p = 0.68). Sixty-one (8%) of 751 babies in the
standard care group were large for gestational age com-
pared with 71 (9%) of 761 in the intervention group
(1.15, 0.83–1.59; p = 0.40).
Recent systematic reviews of postnatal interventions
have highlighted the potential importance of these, but re-
ported gaps in evidence of ‘what works’ and the low qual-
ity of evidence. A Cochrane review of diet and/or exercise
for postnatal weight reduction [22] in which 12 trials con-
tributed data on 910 women found women who exercised
did not lose significantly more weight than women in
usual care groups (two trials, n = 53, mean difference −
0.10 kg, 95% CI − 1.90 to 1.71), but women who took part
in a diet (one trial, n = 45, mean difference − 1.70 kg, 95%
CI − 2.08 to − 0.132) or diet plus exercise programme
(seven trials, n = 573, mean difference − 1.93 kg, 95% CI −
2.96 to − 0.89) lost significantly more weight than women
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in usual care groups. Trials included women who were
obese, overweight, or gained excessive gestational weight,
with recruitment from 3weeks to 24months postpartum.
Intervention duration ranged from 10 to 24 weeks, with
content often delivered as a ‘package’. Only one trial was
from the UK. Despite considerable study heterogeneity,
the authors suggested diet and exercise together rather
than diet alone could help women to lose weight postna-
tally because the former could improve women’s cardio-
vascular fitness level and preserve fat-free mass.
van der Pligt and colleagues completed a systematic re-
view of interventions to reduce postpartum weight reten-
tion across all BMI categories [5]. Studies were included if
postpartum weight was a primary outcome, and diet and/
or exercise and/or weight monitoring were intervention
components. Interventions commenced from 11 days to 9
months postpartum and included counselling, individua-
lised physical activity plans, healthy eating groups, and
clinic visits. Of 11 studies included, 10 were RCTs, none
from the UK. Seven reported a decrease in postpartum
weight retention, six of which included diet and physical
activity delivered by different health professionals. No
study considered cost-effectiveness, with wide heterogen-
eity in intervention implementation. Nevertheless, findings
suggested that postnatal weight loss was achievable, al-
though evidence of optimal setting, implementation, inter-
vention duration, and recruitment approach was unclear.
The potential for postnatal interventions to impact on
other maternal health behaviours was considered in a re-
view by Hoedjes et al. [23] which also reported poor-
quality evidence. Eight of 17 included studies assessed ef-
fects on weight loss, and 9 on smoking cessation and re-
lapse prevention. Of the weight loss studies, five reported
significant effects of combined diet and exercise. Two of
the four studies which assessed smoking relapse prevention
found no evidence of effect. Four studies included inter-
ventions for smoking prevention and prevention of relapse.
Although authors recommended that existing postpartum
lifestyle interventions could support weight loss and smok-
ing cessation or prevent smoking relapse, caution is
needed. There was wide variability in study methods, and
details of study selection, data extraction processes, and as-
sessment of study quality were not provided.
The potential for the postnatal period to be a more ap-
propriate time to consider support for weight manage-
ment and positive lifestyle behaviours is clear, yet high-
quality evidence of effective interventions is lacking.
Based on evidence from general population studies that
commercial organisations may be more effective at sup-
porting weight management than healthcare providers
[24], this trial is being undertaken to assess the feasibility
of conducting a future definitive RCT to determine ef-
fectiveness and cost-effectiveness of lifestyle information
and access to Slimming World® (Alfreton, UK) groups
for a 12-week period, from 8 to 16 weeks postnatally, on
long-term postnatal weight management and positive
lifestyle behaviour among women from an ethnically di-
verse inner city population.
Objectives
The following are the specific trial feasibility and trial
process objectives to inform if a future definitive trial
could be undertaken. Findings will inform if postnatal
women would be prepared to enter a study of weight
management, when would be an optimal time to inter-
vene, content of a pragmatic and accessible intervention, if
an intervention could impact on other health areas, and
outcomes likely to be of most importance in a future trial.
Trial feasibility objectives
The trial feasibility objectives are as follows:
 To assess recruitment and retention rates
 To estimate the effect size for a likely primary study
outcome in a future definitive trial, namely difference
between study groups in weight change from booking
to 12months postbirth, expressed as percentage of
weight change or weight loss in kilogrammes
 To estimate impact of lifestyle information and
access to Slimming World® (Alfreton, UK) groups
on maternal weight change from first antenatal visit
to 12 months postnatally
 To explore influence of lifestyle information and
access to Slimming World® (Alfreton, UK) groups
including weight management, diet, physical activity,
breastfeeding, smoking cessation, alcohol intake,
physical and mental health, infant health, sleep
patterns, body image, self-esteem, and health-related
quality of life at 6 and 12 months postnatally
 To assess resource impacts across different agencies
likely to be of relevance and identify data appropriate
for economic evaluation in a definitive RCT
 To decide if criteria to inform progression to a
definitive RCT have been met
Trial process evaluation objectives
The trial process evaluation objectives are as follows:
 To assess acceptability of trial procedures and
intervention
 To assess variation in Slimming World®
(Alfreton, UK) groups attended by women
 To assess sources of weight management support
accessed by women (in particular assess risk of
contamination) (Table 1)
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Methods and analysis
This protocol paper has been written following the SPIRIT
and TIDieR guidance [25, 26].
Study design
This is a single centre, randomised two-arm feasibility
trial, with a nested mixed-methods process evaluation.
Setting
The study will be conducted in one maternity unit in inner
city London, serving an ethnically diverse population and
providing maternity care for over 6000 women annually.
Target population
The target populations are women who are overweight
(BMI 25–29.9 kg/m2) or obese (BMI ≥ 30 kg/m2) as iden-
tified at their first antenatal contact and women with a
normal BMI (18.5–24.9 kg/m2) at pregnancy booking
who gain excessive gestational weight as assessed at 36
weeks gestation [27]. Women will be eligible for recruit-
ment if they meet the following criteria:
 Aged 18 and over
 Speak and read English
 Expecting a single baby
 Have not accessed weight management groups
during index pregnancy
Exclusion criteria
Women will be excluded if they meet the following criteria:
 < 18 years old
 Insufficient understanding of spoken and written
English
 Current diagnosis of major psychiatric disorder
 Foetus has known abnormality
 Involvement in another postnatal study to reduce
‘burden’ of research participation
 Identified medical complications (for example,
cardiac disease, type 1 diabetes)
 Identified eating disorders
 Previous surgery for weight management
Recruitment
Women with BMIs ≥ 25 will be identified from their
antenatal booking details. At approximately 26 weeks
Table 1 Study objectives, outcomes, criteria for success, and method of analysis
Objectives Feasibility outcomes (trial) Criteria for success Method of analysis
Maternal weight change
(proposed primary endpoint
for future definitive RCT)
Difference in percentage of maternal
weight change between trial groups
from antenatal booking to 12months
postnatally
Percentage of weight change/
weight loss in kilogrammes
Estimated differences/95% CI
calculated (significance at 5%)
Pre-planned sub-group analysis
by BMI category
Recruitment and retention Uptake/time to recruit 190 women
from BMI categories of interest
Complete recruitment within
6 months
Descriptive
Loss to follow-up under 30% at 12 months Retain 130 women to 12 months Descriptive
Explore influence of lifestyle
information and Slimming World
on lifestyle/health behaviours
Dietary intake, EPDS score, breastfeeding
uptake and duration, sleep patterns,
smoking, alcohol consumption,
self-esteem, infant health, body image
High completion of all included
measures at each follow-up point
N (%) for binary and categorical
variables and mean (SD), or
medians/geometric means for
continuous variables
Assess feasibility of collecting
resource utilisation and cost
data
Completion of EQ-5D-5L, Adult Service
Use Schedule, relevant data from
women’s maternity records
High completion of all included
measures at each follow-up point
Multivariate/sensitivity analysis
Objectives Outcomes (process) Criteria for success Method of analysis
Acceptability of trial process
procedures
Reasons for taking part/dropping out,
expectations, understanding of study
aims, attendance at follow-up appointments,
acceptability of surveys
Processes and procedures
acceptable, high completion
of follow-up measures
Framework method, descriptive
Acceptability of intervention Women commence and complete
Slimming World sessions offered
Depth of understanding of barriers
and facilitators to uptake and
retention at sessions, so this can
be maximised in a future trial
Framework method, descriptive
Variation in Slimming World
groups attended by women
by date/time of day
Range of variation in Slimming World
groups attended
Availability of data from Slimming
World
Descriptive
Sources of weight management
support control group accessed/
additional support intervention
women accessed
Extent and type of weight management
support used by control women,
additional support used by intervention
women
Risk of contamination re access to
commercial weight management
support by control group
Descriptive
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gestation, identified women in this group will receive a
study letter which briefly explains study aims and advises
that a research midwife will be in contact within 2 weeks
to explain the study further. The letter will also explain
how the woman can contact researchers if she does not
want to receive further details. The research midwife will
call women who have not asked to be removed from the
contact list.
Women with normal BMIs at pregnancy commence-
ment, but gain excess pregnancy weight as assessed at
around 36 weeks gestation against IoM criteria [27], will
be offered the opportunity to self-refer to the research
midwives, through advertising at the study site and mid-
wifery and obstetric referrals (from around 28 weeks ges-
tation). Women will be asked to contact the research
midwives to arrange to be weighed at around 36 weeks
gestation. If women in this group do not respond to
study advertising within 3months of commencement of
recruitment, a similar opt-out approach for women with
high BMIs will be adopted, following relevant ethics
amendments. An opt-out letter would be sent to all
women with normal BMI at booking at around 32–34
weeks gestation to explore feasibility of this approach.
All women identified will be offered a patient informa-
tion leaflet by research midwives prior to seeking con-
sent at around 36 weeks gestation. Women interested in
participating will be met by research midwives at the
study site to obtain consent and complete the baseline
questionnaire. Women who gain excessive gestational
weight could be recruited at an antenatal appointment if
this takes place around 36 weeks gestation.
All women who are eligible, recruited, and provide writ-
ten consent will be randomised to either of the following:
 Standard care plus lifestyle information and
postnatal access to Slimming World® (Alfreton, UK)
weight management groups
 Standard care only
A screening form will be completed by the research
midwife to record women approached, their eligibility,
and at what point women may have declined to take part
(when first approached or at consent) and reasons for
this, if women are willing to provide information.
A separate patient information leaflet will be mailed to
recruited women purposively selected from both trial
groups and invited to participate in a telephone or face
to face interview at 12 months postnatally. Similarly,
women allocated to the intervention who are purposively
selected for interview about their experiences on com-
pletion of their Slimming World® (Alfreton, UK) groups
will be sent a separate study information leaflet to seek
consent to participate in this stage of the study process
evaluation.
Treatment allocation and randomisation
Randomisation and allocation will be carried out by
KCL’s Clinical Trials Unit web-based system. Women
will be registered on the InferMed MACRO web-based
data entry system by a research midwife prior to ran-
domisation to allocate each a unique study number
‘PIN’. Research midwives will access the system and,
using the PIN, initials, and date of birth, request ran-
domisation. Unit of randomisation will be individual
participant, allocated in a ratio of 1:1 to intervention and
control. Selection bias will be minimised by ensuring all
women eligible and recruited have equal opportunity of
being allocated to each study group and follow-up com-
pleted, with information on women randomised and al-
located but who opt out presented but clearly indicated
as such. Use of intention to treat (ITT) analysis will limit
attrition and analytical bias.
Blinding
It will not be possible to ‘blind’ research midwives or
women to allocation. Those responsible for analysis will
be blinded to allocation.
Interventions
Standard care (described below), plus information on
positive lifestyle behaviours from late pregnancy and ac-
cess to a 12-week weight management group (Slimming
World® (Alfreton, UK)) commencing from 8 weeks up to
16 weeks postnatal (see Fig. 1 flow chart).
An evidence-based positive lifestyle leaflet reflecting
current NICE guidance on breastfeeding, diet, importance
of smoking cessation/prevention of relapse, reducing alco-
hol, and managing sleep [10, 28] will be offered to women
allocated to the intervention.
Slimming World® (Alfreton, UK) content is underpinned
by group behaviour change techniques targeted to support
individuals make healthier food choices and increase phys-
ical activity (www.Slimmingworld.co.uk). Groups are run
using a standardised approach, with in-built quality assess-
ment procedures [7]. Behaviour change techniques are
supported by social cognitive theory, with a focus on mo-
tivation and self-efficacy for weight management and re-
ducing relapse, including goal setting, self-monitoring,
social support, and positive reinforcement [29, 30].
Consultants who lead groups receive standardised train-
ing overseen by Slimming World® (Alfreton, UK) dietitians
and nutritionists which includes motivational techniques
to support positive lifestyle changes to manage weight, nu-
trition, food facts, and role of exercise and activity in health
and weight management. Groups follow a standard format,
starting with a weigh in, followed by discussion of group
member’s experiences of weight management to help
change habits, share healthy swaps, and discuss what to
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eat. Sessions can include basic cooking skills, taking cost,
cultural preferences, and time constraints into account.
A food optimising system encourages adherence to
healthy eating, and physical activity encouragement
includes facilitation of behaviour change, redefining
what ‘activity’ can include. Slimming World® (Alfreton,
UK) will record initial and ongoing attendance and
weekly weight. Women can attend for up to 12 groups
Fig. 1 CONSORT study flow diagram for supporting women with postnatal weight management (SWAN) feasibility trial
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at no-cost, which run over 14 consecutive weeks to allow
2 ‘holiday’ weeks within offer. After this time, women
can choose to continue and pay the standard weekly fee.
A research midwife will contact women at 8 weeks
postnatally to provide a dedicated Slimming World®
(Alfreton, UK) telephone number for member services.
A Slimming World® (Alfreton, UK) consultant will pro-
vide the woman with information on the local groups
she can join, times, and venue (standard practice).
Women can choose which group they attend and when
they commence groups within the 8 to 16 week ‘window’
to fit with their health, lifestyle, and family demands.
Women can take their babies with them.
We will assess adherence to allocation protocols, loss to
follow-up, and women’s views of acceptability and sustain-
ability. To capture data on whether women attend for
each complete Slimming World® (Alfreton, UK) group
session or leave after the initial weigh-in, we will ask
women to complete in their follow-up questionnaires how
many groups they attended and stayed for the whole ses-
sion. Follow-up will capture data on women who continue
attending groups or achieve their goal and stop attending
to compare outcomes of interest with the control group.
Slimming World’s® (Alfreton, UK) quality assurance
procedures ensure standardisation of weight manage-
ment groups, including weekly calls between group con-
sultants and their team managers. As consultants are
from the local area, they will be aware of cultural prefer-
ences, time, and budget constraints women face and can
advise on basic cooking skills and local shops selling
healthy foods within women’s budgets. The Food Opti-
mising system used in Slimming World® (Alfreton, UK)
groups includes pictorial use of recipes for individuals
who may not have a high level of understanding of writ-
ten English. As our postnatal population is geographic-
ally mobile [31], women who move from the area can
transfer their group membership to another local group
anywhere in the UK.
Women from both trial groups will be asked to attend
an appointment with a research midwife to be weighed ei-
ther at the study site or at their home at 6 and 12months.
Travel costs and £10 Love2Shop voucher to thank women
for their time will be offered.
Standard care
Women allocated to standard care only will receive stand-
ard NHS maternity care to 8 weeks postnatal. This could
include, for example, routine midwifery and health visitor
contacts for infant feeding assessment and assessment of
birth recovery. Women will be offered a routine contact
with their GP at around 6–8 weeks postnatally. We will ask
all recruited women at their 6 and 12month follow-up
about their experiences of using weight management
groups or other sources of support for weight management,
healthy lifestyle, and activity.
Trial objectives
Feasibility objectives reflect MRC guidelines for complex
interventions [32] with important exceptions. The aim is
not to evaluate the intervention itself. Slimming World®
(Alfreton, UK) groups are ‘standardised’, with robust
mechanisms to ensure intervention fidelity. Our process
evaluation is not designed to answer some questions seen
in complex evaluations regarding generalizability of the
intervention, assurance that implementation/delivery of
the intervention is consistent across sites, or determine
mechanisms of impact. This study reflects a pragmatic
trial approach—evaluating the impact of an intervention
where women can choose which group to attend and can
switch groups, exactly as if they were a ‘standard’ self-
referred member of Slimming World® (Alfreton, UK).
Trial feasibility objectives
The primary feasibility objective is to estimate the effect
size for a likely primary study outcome in a future de-
finitive trial, namely difference between study groups in
weight change from booking to 12months postbirth,
expressed as percentage of weight change or weight loss
in kilogrammes. Mean percentage change across all
women gives greater power, and fewer women will need
to be recruited. We will undertake pre-planned sub-
group analysis of the primary assessment in women of
different booking BMI categories. The primary endpoint
for a future trial will be selected on grounds of power.
Other objectives include those most appropriate to
support meeting the primary objective and inform pro-
gress to a definitive RCT. These will include rates of 5%
and 10% weight reduction and changes in relation to as-
pects of healthy lifestyle and health behaviours, including
diet and nutrition, breastfeeding, physical activity, smok-
ing cessation, alcohol intake, self-esteem, and body
image. Some included measures have been validated in
relevant populations, including among women of repro-
ductive age and women who have recently given birth.
Measures will be included in questionnaires at 6 and
12months postnatally. Those marked with ‘**’ will also
be included in the baseline questionnaire. Question-
naires will be ‘tailored’ for the intervention or standard
care arm, to enable questions on uptake of support for
weight management to be included at 6 and 12months
to inform trial process outcomes:
 Dietary intake: The Dietary Instrument for Nutritional
Education (DINE© University of Oxford)** [33]
 Soft drink intake: questions developed for the study
 Physical activity: The International Physical Activity
Short-Form** [34]
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 Mental health: Edinburgh Postnatal Depression
Scale [35]
 Breastfeeding intent**, uptake, and duration,
questions developed for study
 Sleep patterns: questions developed for the study
 Smoking: smoking status/cigarette dependence** [36]
 Alcohol consumption: Alcohol Use Disorders
Identification Test** [37]
 Self-esteem: Rosenberg Self-Esteem Scale** [38]
 Infant health: questions developed for study
 Impact on body image [39]
 Resource utilisation and costs outcome measures: the
EQ-5D-5L** and the Adult Service Use Schedule** [40]
Trial process evaluation objectives
The process evaluation will focus on the following key
aspects:
 The acceptability of study processes and procedures
 The acceptability of the intervention and how it is
experienced by women (those who complete at least
10/12 Slimming World® (Alfreton, UK) groups and
those who do not; those who complete each group
attended for the full session or leave after being
weighed; those who continue to attend Slimming
World® (Alfreton, UK) groups on completing the
intervention and those who do not)
 The likely variation in groups attended by women in
relation to date/time of day, and whether women stay
with one consultant/group or try different groups
 Sources of weight management support control
group women may have accessed; additional sources
of weight management support intervention group
women may have accessed
Data will be collected using questionnaires and semi-
structured interviews with a sub-sample of women.
Questionnaires at 6 and 12months include sections de-
signed to capture information on weight management
views and use of strategies among all women, and on
Slimming World® (Alfreton, UK) attendance, barriers,
and facilitators among intervention women only.
Semi-structured qualitative interviews will be conducted
at two time points with intervention women (n = approx.
10 women at 6months; 15–20 at 12months) to explore
the acceptability and sustainability of the intervention, and
acceptability of trial procedures. This will include targeting
women who did and did not join Slimming World® (Alfre-
ton, UK), those who did/did not attend the 12 sessions of-
fered, and those who did/did not lose weight. At 12
months, a sub-sample of control group women will also be
interviewed to explore study processes and experiences of
participating, including reasons for taking part/dropping
out, recruitment and randomisation (expectations/
understanding of the study aims), views on outcome mea-
sures, attendance for weighing appointments as part of
study follow-up, and lifestyle behaviours. Topic guides for
both groups will be informed by the COM-B model of be-
haviour change [41], exploring barriers and facilitators to
weight management/the intervention according to capabil-
ities, opportunities, and motivations. Control group women
will be asked about the impact, if any, of participating on
their levels of physical activity or any dietary changes.
Telephone or face to face interviews will be offered.
Sampling will be based on maximum diversity in relation
to age, parity, ethnicity, and socio-economic status and
reflect the range of weight loss/gain of the sample.
Health economics
The health economic component will review quality and
completeness of economic data generated by the trial itself
(e.g. women’s self-report data on service contacts and
quality of life outcomes, data from women’s maternity re-
cords) and data from external sources (e.g. unit cost data
for costing service contacts and estimating intervention
costs) necessary for conducting an economic evaluation in
a future definitive trial. An assessment will also be under-
taken of suitability of existing economic models that could
support additional modelling of longer-term (out of trial)
resource impacts and health outcomes linked to observed
(within trial) impacts on weight loss as part of a definitive
trial. This will identify whether or what additional evi-
dence and modelling would need to be undertaken to sup-
port evaluation of longer-term costs and outcomes.
The health economic component will include primary
analysis of economic data generated by the trial to gain
preliminary insight into intervention cost-effectiveness.
This will include the following:
 Analysis of differences in overall costs between trial
groups, including service contacts, clinical resource
use, and weight management intervention costs.
Sub-group effects on differences in costs between
groups will be explored with specific reference to
baseline BMI. This, with evidence on sub-group
analysis of weight loss outcomes, will inform whether
a definitive trial should be designed to evaluate
variability in intervention cost-effectiveness between
relevant sub-groups.
 A preliminary within trial cost-effectiveness analysis
of the weight management intervention versus
standard care using comparative feasibility trial
data on resource use and costs and quality of life
outcomes over a 12-month follow-up.
Sample size calculation, selection, and loss to follow-up
A sample size of 190 women will allow a 30% loss to
follow-up to ensure we achieve our required sample size
Bick et al. Pilot and Feasibility Studies           (2019) 5:117 Page 8 of 12
of 130 women. This study is designed firstly to establish
the rates at which women could be recruited and
retained in a future definitive RCT and estimate critical
parameters with necessary precision to inform sample
size requirements. In particular, we require estimates of
the standard deviation, and design effect for the primary
endpoint, allowing for clustering by intervention group.
One hundred thirty women will allow estimates of the
required sample size for any given clinically important
difference to within 30% of the true value.
Based on published data [17, 42] the mean (SD) per-
centage weight change following a Slimming World®
(Alfreton, UK) programme of 12 weekly groups is − 5.5%
(3.3). Assuming these numbers are typical, 65 women in
each group (130 in all) would be required to detect a dif-
ference of 2% between active and control groups with
90% power. Of around 6600 women who give birth at
the reference maternity unit over 12 months in 2017,
40% were overweight, 15% of whom were obese. Data on
women with excessive GWG are not routinely collated.
Potentially, 55 women booking each week would meet
obese/overweight inclusion criteria. Recruiting 7–8
women each week over an 8-month (32 week) period
would be sufficient to achieve the desired sample size to
meet the aims of this feasibility study.
Compliance issues are an important consideration. Loss
to follow-up among postnatal women can range from 30
to 40% [43, 44]. Experience of research in similar popula-
tions has shown that planned initiatives including flexible
follow-up appointments, travel expenses, vouchers for
returning questionnaires, and sending of reminders can
reduce loss to follow-up. Follow-up appointments will be
offered at weekends and week days, with the option to
complete questionnaires at these appointments.
Analysis
Process data will be analysed separately before examin-
ing relationships between quantitative and qualitative
data, with synthesis completed in line with O’Cathain
et al. [45]. Quantitative data will be entered onto the
MedSciNet web-based data entry system. Retention and
adherence will be considered from recruitment rate,
consent rate, withdrawal and loss to follow-up (with rea-
son), departures from randomised treatment, and preva-
lence of SAEs reported by treatment group and overall.
Estimated differences and 95% confidence intervals will
be calculated for specified primary and secondary ana-
lyses (significance at 5%). Sensitivity analyses will assess
robustness of conclusions to missing outcome data and
departures from randomised treatment. Analyses of po-
tential efficacy will be based on the ITT sample, utilising
follow-up data from all randomised women.
Differences between arms will be compared at 6 and
12months postbirth adjusting for important prognostic
factors (parity, maternal age, ethnicity, BMI at booking,
and (as appropriate) baseline measurement). Data to in-
form process outcomes will be evaluated using descrip-
tive analysis. Numbers (with percentages) will be
presented for binary and categorical variables and means
(standard deviations), or medians (with lower and upper
quartiles) or geometric means for continuous variables
will be presented. Stata version 15.1 or later will be used
for analyses (StataCorp, College Station, TX).
Interviews will be recorded with women’s permission
and transcribed and analysed using the framework
method for thematic analysis [46]. Analyses will be de-
ductively informed by the COM-B model for behaviour
change [41]. Themes that emerge inductively will be
captured, and efforts made to identify and explore dis-
confirming/outlier cases. Key topics and issues will be
identified through familiarisation with transcripts by two
researchers who will initially work independently and
then together to discuss and agree the final coding
framework with a third researcher. A series of thematic
charts will be developed according to the coding frame-
work, and data from each transcript summarised under
each theme, enabling examination of similarities and dif-
ferences of views within and between transcripts, and
use of a constant comparative approach. Quantitative
and qualitative data on acceptability of the intervention
and other aspects of feasibility will be integrated using
mixed-methods matrices [46].
Economic analysis
Economic analyses will be conducted from an NHS/per-
sonal social services perspective on the assumption that if
the intervention were commissioned for the target popula-
tion, full costs would be met from NHS or local authority
public health resources. A review of evidence will be com-
pleted to assess if the wider evidence base would support
economic modelling of impacts in a future study.
Data on self-reported service use for specific service
items will be collected using a modified version of the
Adult Service Use Schedule (AD-SUS). Service use for in-
dividual items between intervention and control groups
will be compared descriptively (means, range, and stand-
ard deviations). Service contacts will be costed using exist-
ing published unit cost data. Trial participants allocated to
the intervention will be allocated an intervention cost
based on prices charged by the provider organisation.
Total costs from baseline to completion of follow-up (12
months) will be calculated for each participant as the sum
of the cost of all service contacts plus intervention costs
(for the intervention group).
Differences in mean total costs between trial groups will
be evaluated through multivariate analysis controlling for
baseline covariates. Interaction effects between the
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treatment allocation variable and variables identifying
baseline BMI groupings will be used to test for sub-group
effects. The base-case analysis will evaluate the mean cost
difference on a complete case basis and based on intention
to treat (ITT).
EQ-5D-5L data at baseline and follow-up will be used
to evaluate quality of life outcomes in terms of a quality
adjusted life year (QALY) equivalent over the 12-month
follow-up period. Multivariate analysis will evaluate the
mean difference in QALY outcomes between trial
groups adjusting differences in baseline covariates. Mean
QALY differences will be combined with mean cost dif-
ferences to evaluate cost-effectiveness on a complete
case and ITT basis. Sampling uncertainty will be mod-
elled using a simulated non-parametric bootstrap distri-
bution of cost and QALY difference pairings within the
cost-effectiveness plane and through subsequent gener-
ation of a cost-effectiveness acceptability curve (CEAC).
Sensitivity analysis will include the effects of missing
data on base-case conclusions and sensitivity of esti-
mated mean cost differences to alternative multivariate
modelling specifications, and sensitivity to departures to
randomised treatment.
Monitoring
The trial will be supervised by an independent Trial
Steering Committee (TSC). An independent data moni-
toring committee (DMC) is not required to oversee the
safety of subjects in the trial. As this is not a clinical trial
of an investigational medical product, the TSC will take
overall responsibility for trial conduct.
Data management
Quantitative data will be collected using specific study
data collection forms, and processed and monitored cen-
trally for consistency, viability, and quality by the Core
Project Team. Data will be screened for out-of-range data,
cross-checked for conflicting data within and between col-
lection forms using computerised logic checking screens,
and processed using a double data-entry system by an in-
dependent data clerk. The trial statistician will monitor
data for consistency, viability, and quality using a bespoke
data management system (MedSciNet Ltd., Stockholm,
Sweden). The MedSciNet programmer will run trial-
specific programmes to extract certain fields from the
database (as requested by the chief investigator or trial
statistician), cross-check certain information, and, with
the chief investigator, review results generated for logic
and any patterns or problems.
Patient and public involvement
The original research questions, study design, interven-
tion, and outcomes were developed with the support of
six local women who had commenced pregnancy with
higher BMIs and had experienced support of weight
management both during and after pregnancy. To sup-
port the study as it progresses, four of these women will
form an Expert Patient Group which will meet three
times a year to discuss study progress, overcoming any
barriers to recruitment, content and completion of base-
line and follow-up questionnaires, interview schedules,
access and take up of the intervention, and implications
of findings for a future definitive RCT. All women re-
cruited will be offered the opportunity to receive a sum-
mary report of the trial.
Confidentiality
All data from maternity records, questionnaires, inter-
views, and Slimming World® (Alfreton, UK) on women’s
attendance and weight management progress will be
anonymised, kept confidential, and managed in accord-
ance with the Data Protection Acts 1998 and 2018, NHS
Caldicott Guardian, the Research Governance Framework
for Health and Social Care, and Research Ethics Commit-
tee Approval. Each woman will be allocated a unique
study reference number. All records will be kept in a se-
cure storage area with limited access. Clinical information
will not be released without the written permission of the
participant, except as necessary for monitoring and audit-
ing by the sponsor, its designee, regularity authorities, or
the REC. No patient identifiable data will be used in any
publications or presentations relating to this study.
Ethics and dissemination
Study findings will be published in high impact journals, in
line with the CONSORT guidance [47]. Our expert PPI
group will advise on dissemination of findings relevant for
women and their families, in line with the INVOLVE guid-
ance. Slimming World® (Alfreton, UK) will have no access
to trial data or be involved in any aspect of trial analysis or
interpretation of trial results. The funders will have no role
in trial analysis or interpretation of trial results.
Discussion
This feasibility trial is designed to provide robust data
on whether it is possible to undertake a future definitive
RCT of a postnatal weight management and lifestyle be-
haviour intervention among women from an ethnically
diverse inner city setting. Support for weight manage-
ment is important, given the longer-term health impacts
of a higher BMI at pregnancy commencement, or as a
consequence of gaining EGWG, on women and their
children, but evidence of how best to support these
women is lacking. Prior to undertaking a definitive RCT
of effectiveness, evidence is needed to see if such a trial
could be undertaken, if postnatal women would be
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prepared to enter a study of weight management, when
would be an appropriate time to offer such an interven-
tion, if a weight management intervention could impact
on other positive health behaviours, confirm outcomes
likely to be of most importance in a future trial, and if
criteria to proceed to a definitive trial have been met.
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